Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• T-cell redirecting bispecific antibodies (TRBAs) and chimeric antigen receptor (CAR)-T cells are immunotherapy platforms with decades-old concepts, now rapidly advancing.
• Two TRBAs and two CAR-T cell products have gained regulatory approval for hematologic cancers in the last decade.
• Numerous TRBA (53) and CAR-T cell (246) constructs are currently in clinical trials.

Purpose of the Study:

• To review the current status and future directions of TRBA and CAR-T cell therapies.
• To compare the mechanisms, efficacy, and safety profiles of TRBAs and CAR-T cells.
• To discuss challenges and ongoing developments for optimizing these immunotherapies.

Main Methods:

• Review of approved therapies and ongoing clinical trials for TRBAs and CAR-T cells.
• Comparison of TRBA formats (e.g., BiTEs, IgG-like) and CAR-T cell types (autologous vs. allogeneic).
• Analysis of immunological synapse formation and clinical safety data (cytokine release syndrome, neurotoxicity).

Main Results:

• TRBAs and CAR-T cells demonstrate high efficacy in clinical trials for hematologic malignancies.
• Distinct immunological synapse formations are observed between TRBA- and CAR-T cell-mediated cytotoxicity.
• Both platforms share safety concerns, including cytokine release syndrome and neurotoxicity.

Conclusions:

• TRBAs and CAR-T cells represent a new era in cancer treatment, with ongoing innovation in formats and dosing.
• Addressing challenges like target heterogeneity and the tumor microenvironment is crucial for expanding their use to solid tumors.
• Future research focuses on maximizing efficacy while minimizing toxicity for broader patient benefit.